Ariel Jones

Urban Health Today

In the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) study, researchers explored whether population-based screening for monoclonal gammopathy of undetermined significance (MGUS) could increase the frequency of patients with multiple myeloma being diagnosed in the precursor state. According to findings from the study presented at the 2021 American Society of Hematology Annual Meeting, systematic screening identified a significantly higher number of patients with active malignancy or smoldering disease, suggesting that early detection and intervention are achievable.Even though individuals who develop multiple myeloma during screening for the precursor state MGUS have better overall survival and fewer complications than patients with multiple myeloma diagnosed without knowledge of MGUS, &ldquo;less than 5% of all multiple myeloma patients are diagnosed during their precursor state,&rdquo; the study authors wrote.iStopMM researchers invited all Icelandic residents born before 1976 to participate in MGUS screening. A total of 75,422 participants provided a serum sample for analysis. Of those, 3,725 newly diagnosed individuals with MGUS were identified and 3,487 were enrolled in the follow-up randomized controlled portion of the trial.In the randomized portion, patients with MGUS were either not contacted (arm 1), followed based on current guidelines (arm 2), or followed with a more intensive diagnostic and monitoring strategy (arm 3). Individuals who progressed to multiple myeloma were offered early treatment, and all participants routinely submitted quality of life and mental health questionnaires.Researchers reported that MGUS prevalence was higher in males at 5.9% versus 4.1% (p &lt; 0.0001). Prevalence was also correlated with age, with 2.3%, 6.2%, and 12.9% of patients diagnosed in respective age groups of 40 to 59, 60 to 79, and 80 to 103 years.After a median follow-up of three years, 194 patients had been diagnosed with any lymphoproliferative disorder&mdash;specifically, nine patients in arm 1, 92 in arm 2, and 133 in arm 3 (p &lt; 0.001). The difference between arms was statistically significant for all lymphoproliferative disorders combined, and for smoldering Waldenstr&ouml;m macroglobulinemia, smoldering myeloma, and multiple myeloma diagnoses.The initial analysis of the iStopMM data suggest that &ldquo;early detection and intervention is achievable,&rdquo; according to the investigators. However, though they called the findings encouraging, they advised against systematic MGUS screening in healthy individuals until the iStopMM study concluded and final results including survival and quality of life data are available.

Rebecca Araujo

AI-Driven Insulin Support: Are These Tools Ready for Diabetes Care?

Diabetes

Lou Portero

Heart Rate Complexity May Predict Cognitive Decline in Older Adults

Alzheimer's & Dementia

Female Cancer Survivors Face Higher Rates of Fatigue and Depression, Study Finds

Women's Neurology

Latest News

iStopMM: Screening for MGUS Enables Earlier Detection and Intervention

Multiple Myeloma

In the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) study, researchers explored whether ...

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe